Lancet January 02, 1999

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

CIBIS-II Investigators and Committees

Bottom Line

In stable patients with chronic heart failure and reduced ejection fraction, the addition of the beta-1 selective blocker bisoprolol to standard therapy significantly reduced all-cause mortality and sudden cardiac death.

Key Findings

1. The trial was stopped early after the second interim analysis due to a highly significant mortality benefit in the bisoprolol arm.

2. All-cause mortality, the primary endpoint, was significantly lower in the bisoprolol group compared to the placebo group (11.8% vs. 17.3%; Hazard Ratio [HR] 0.66, 95% CI 0.54-0.81, p<0.0001).

3. Bisoprolol significantly reduced the rate of sudden cardiac death compared to placebo (3.6% vs. 6.3%; HR 0.56, 95% CI 0.39-0.80, p=0.0011).

4. All-cause hospital admissions were significantly reduced with bisoprolol (33.6% vs. 39.6%, p=0.0006), as well as hospital admissions for worsening heart failure (11.9% vs. 17.6%, p=0.0001).

5. The treatment benefits were observed independently of the severity or underlying etiology (ischemic vs. non-ischemic) of the heart failure.

Study Design

Design

RCT

Double-Blind

Sample

2,647

Patients

Duration

1.3 yr

Median

Setting

Multicenter, Europe

Population Symptomatic patients with NYHA class III or IV heart failure, left ventricular ejection fraction ≤35%, receiving standard therapy including diuretics and ACE inhibitors

Intervention Bisoprolol 1.25 mg daily, progressively titrated up to a maximum tolerated dose of 10 mg per day

Comparator Placebo

Outcome All-cause mortality

Study Limitations

• The trial was stopped early for efficacy, a design element that can sometimes overestimate the true magnitude of the treatment effect.

• Patients with severe class IV symptoms and recent acute instability were underrepresented, meaning the safety and efficacy of initiating bisoprolol in the most severely decompensated patients was not fully established.

• The study population was predominantly male (approximately 80%) and relatively young (mean age 61 years), potentially limiting generalizability to older patients and women.

• The follow-up period was relatively short (mean 1.3 years) due to early termination, preventing assessment of longer-term safety and efficacy trajectories.

Clinical Significance

CIBIS-II was a landmark trial that definitively cemented the role of beta-blockers as foundational, life-saving therapy in chronic heart failure with reduced ejection fraction (HFrEF). By demonstrating a massive 34% relative risk reduction in all-cause mortality and a 44% reduction in sudden death, it established that adding a cardioselective beta-blocker to standard ACE-inhibitor and diuretic therapy transforms patient survival. This directly influenced global guidelines to mandate beta-blockers as standard-of-care for stable HFrEF patients.

Historical Context

For decades, beta-blockers were considered strictly contraindicated in heart failure due to their negative inotropic effects, which clinicians feared would worsen cardiac output. The paradigm began to shift in the 1990s as evidence emerged that blocking chronic sympathetic nervous system overactivation prevented maladaptive cardiac remodeling. While earlier trials like CIBIS-I and the US Carvedilol trial suggested potential benefits, CIBIS-II (published concurrently with MERIT-HF) provided the unassailable, highly powered mortality data needed to overturn decades of medical dogma, revolutionizing the modern pharmacological management of heart failure.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Before trials like CIBIS-II, beta-blockers were historically contraindicated in heart failure. Based on the pathophysiology of heart failure and the pharmacology of bisoprolol, why were they originally feared, and what compensatory mechanism are they actually mitigating to provide a mortality benefit?

Key Response

This addresses foundational pathophysiology. Beta-blockers are negative inotropes, which acutely worsen cardiac output in a failing heart. However, chronic heart failure is driven by maladaptive sympathetic nervous system overactivation. Bisoprolol blocks this chronic catecholamine toxicity, preventing pathological cardiac remodeling, myocyte apoptosis, and arrhythmias, thus providing a long-term mortality benefit.

Resident

In CIBIS-II, patients were initiated on bisoprolol at a very low dose of 1.25 mg and titrated slowly over months. How does this protocol inform your practical management of a patient recently admitted for acute decompensated heart failure who was not previously on a beta-blocker?

Key Response

This highlights a critical clinical pearl. Because beta-blockers acutely reduce inotropy, initiating or up-titrating them during a 'wet' or decompensated state can precipitate hemodynamic collapse. The CIBIS-II protocol reinforces the 'start low and go slow' approach, waiting until the patient is euvolemic and stable before initiation.

Fellow

CIBIS-II demonstrated a striking 44 percent reduction in sudden cardiac death. Considering the electrophysiologic effects of sympathetic blockade and the specific mechanism of bisoprolol, how does this finding influence the timing and decision-making for primary prevention ICD placement in newly diagnosed HFrEF patients?

Key Response

Fellows must integrate trial data with device guidelines. The massive sudden cardiac death reduction seen in CIBIS-II underpins the modern requirement to wait 3 to 6 months on optimal guideline-directed medical therapy (GDMT) before placing an ICD. Bisoprolol directly raises the ventricular fibrillation threshold and promotes reverse remodeling, often improving EF above the 35 percent ICD threshold.

Attending

CIBIS-II was stopped early for efficacy, a common phenomenon in landmark cardiology trials. How does early trial termination affect the point estimate of the treatment effect, and how should this influence how you counsel patients on the magnitude of expected benefit from bisoprolol?

Key Response

This addresses the 'random high' or truncation-for-benefit bias. Trials stopped early often exaggerate the true treatment effect size because they are halted at a peak of statistical fluctuation. Attendings should recognize this to provide realistic, tempered expectations of absolute risk reduction when counseling patients, rather than quoting potentially inflated early-stopping estimates.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The trial used an interim analysis design that led to premature termination. From a statistical perspective, what are the specific risks of inflation of the Type I error rate with multiple interim looks, and how do strict stopping boundaries (like O'Brien-Fleming) mitigate this in time-to-event analyses such as CIBIS-II?

Key Response

This evaluates advanced statistical methodology. Multiple interim analyses increase the cumulative probability of a false positive (alpha inflation). PhDs should understand how alpha-spending functions, such as O'Brien-Fleming boundaries, require extremely conservative p-values early in the trial to preserve the overall 0.05 Type I error rate across the life of the study.

Journal Editor

A critical reviewer examining the CIBIS-II manuscript might note the exclusion of patients with recent myocardial infarction or unstable angina. How does this exclusion criterion impact the external validity of the sudden cardiac death findings, and what would an editor demand regarding the generalizability of these results to the broader ischemic cardiomyopathy population?

Key Response

Journal editors focus on threats to validity. Excluding acute ischemic events enriches the trial for a more stable population. A tough reviewer would flag that the baseline risk of sudden cardiac death and the relative impact of bisoprolol might differ significantly in patients with active ischemia, demanding clear editorial acknowledgment of this limitation in external validity.

Guideline Committee

CIBIS-II, alongside MERIT-HF and COPERNICUS, established beta-blockers as Class 1 therapy for HFrEF. How do current ACC/AHA guidelines differentiate between the specific beta-blockers proven in these trials versus the class as a whole, and what level of evidence justifies restricting the recommendation to specific agents?

Key Response

Guideline committees must operationalize trial data. The current ACC/AHA guidelines give a Class 1, Level of Evidence A recommendation specifically for bisoprolol, carvedilol, and sustained-release metoprolol succinate, explicitly stating that beta-blocker benefits in HFrEF are not a universal class effect (as evidenced by trials like COMET). This highlights the strict translation of specific trial interventions into modern guidelines.

Clinical Landscape

Noteworthy Related Trials

1999

MERIT-HF Trial

n = 3,991 · Lancet

Tested

Metoprolol CR/XL

Population

Patients with symptomatic heart failure and LVEF <= 40%

Comparator

Placebo

Endpoint

All-cause mortality

Key result: Metoprolol CR/XL significantly reduced all-cause mortality by 34% compared to placebo.

2001

COPERNICUS Trial

n = 2,289 · NEJM

Tested

Carvedilol

Population

Patients with severe heart failure (symptoms at rest or minimal exertion, LVEF < 25%)

Comparator

Placebo

Endpoint

All-cause mortality

Key result: Carvedilol reduced the risk of death by 35% in patients with severe heart failure.

2005

SENIORS Trial

n = 2,128 · Eur Heart J

Tested

Nebivolol

Population

Elderly patients (>= 70 years) with a history of heart failure

Comparator

Placebo

Endpoint

Composite of all-cause mortality or cardiovascular hospital admission

Key result: Nebivolol significantly reduced the primary composite endpoint by 14% compared to placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis